

SmartPill Wireless Motility Capsule

Table of Content

[Purpose](#)
[Description & Definitions](#)
[Criteria](#)
[Coding](#)
[Document History](#)
[References](#)
[Special Notes](#)
[Keywords](#)

[Effective Date](#) 2/2006
[Next Review Date](#) 1/15/2024
[Coverage Policy](#) Medical 212
[Version](#) 5

All requests for authorization for the services described by this medical policy will be reviewed per Early and Periodic Screening, Diagnostic and Treatment (EPSDT) guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member's condition. Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*.

Purpose:

This policy addresses the medical necessity of SmartPill Wireless Motility Capsule.

Description & Definitions:

SmartPill Wireless Motility Capsule is a diagnostic device that measure the pH, pressure, temperature and motility of the gastrointestinal tract.

Criteria:

SmartPill Wireless Motility Capsule is considered **not medically necessary** for any indication.

Coding:

Medically necessary with criteria:

Coding	Description
	None

Considered Not Medically Necessary:

Coding	Description
91112	Gastrointestinal transit and pressure measurement, stomach through colon, wireless capsule, with interpretation and report.

U.S. Food and Drug Administration (FDA) - approved only products only.

Document History:

Revised Dates:

- 2019: September
- 2016: January, April, November
- 2015: June, December
- 2014: March
- 2013: May
- 2012: April, December
- 2011: May, September
- 2010: May
- 2009: April
- 2008: August

Reviewed Dates:

- 2023: January
- 2022: January
- 2021: January
- 2020: January
- 2018: November
- 2017: November
- 2016: June
- 2007: November

Effective Date:

- February 2006

References:

Including but not limited to: Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2022). Retrieved Nov 09, 2022, from Hayes, Inc:

<https://evidence.hayesinc.com/search?q=%257B%2522text%2522:%2522Motility%2520capsule%2522,%2522title%2522:null,%2522termsource%2522:%2522searchbar%2522,%2522page%2522:%257B%2522page%2522:0,%2522size%2522:50%257D,%2522type%2522:%2522all%2522,%2522sources%2>

(2022). Retrieved Nov 09, 2022, from AIM Specialty Health: <https://aimspecialtyhealth.com/>

(2022). Retrieved Nov 09, 2022, from National Comprehensive Cancer Network: <https://www.nccn.org/search-result?indexCatalogue=nccn-search-index&searchQuery=motility%20capsule&wordsMode=AllWords>

(2022, May 18). Retrieved Nov 09, 2022, from MCG: <https://careweb.careguidelines.com/ed26/index.html>

(2022). Retrieved Nov 09, 2022, from Department of Medical Assistance Services:

<https://vamedicaid.dmas.virginia.gov/global-search?keys=motility+capsule>

(2022). Retrieved Nov 09, 2022, from PubMed:

<https://pubmed.ncbi.nlm.nih.gov/?term=wireless+motility+capsule&filter=simsearch1.fha&filter=simsearch2.ffrt&filter=years.2022-2022>

(2022). Retrieved Nov 09, 2022, from Google, Inc:

https://www.google.com/search?q=Professional+recommendations+for+smartpill+wireless+motility+capsule&rlz=1C1GCEA_enUS982US982&oq=Professional+recommendations+for+smartpill+wireless+motility+capsule&aqs=chrome..69i57j33i10i160i5j33i10i299i2.13735j0j4&sourcei

510(k) Premarket Notification - gastrointestinal motility system, capsule. (2022, Nov 07). Retrieved Nov 09, 2022, from Food and Drug Administration: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K092342>

LCD: Wireless Gastrointestinal Motility Monitoring Systems (L33455). (2021, Sep 09). Retrieved Nov 09, 2022, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/search-results.aspx?keyword=iontophoresis&keywordType=starts&areald=s53&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all>

Lembo, A. (2021, Jan 12). Overview of gastrointestinal motility testing. Retrieved Nov 09, 2022, from UpToDate: https://www.uptodate.com/contents/overview-of-gastrointestinal-motility-testing?search=motility%20capsule&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#

Gastroparesis. (2020, Jun 30). Retrieved Jan 04, 2022, from DynaMed: https://www.dynamedex.com/condition/gastroparesis#OTHER_IMAGING_STUDIES

Guidelines. (2022). Retrieved Jan 04, 2022, from American College of Gastroenterology: <https://gi.org/guidelines/>

Validation of Diagnostic and Performance Characteristics of the Wireless Motility Capsule in Patients With Suspected Gastroparesis. (2018, Dec 14). Retrieved Jan 04, 2022, from Clinical Gastroenterology and Hepatology: [https://www.cghjournal.org/article/S1542-3565\(18\)31381-8/fulltext](https://www.cghjournal.org/article/S1542-3565(18)31381-8/fulltext)

Wireless Capsule Systems For Diagnosis Of Gastroparesis And Monitoring Of Gastrointestinal Motility. (2021, Jan 19). Retrieved Jan 04, 2022, from Hayes, Inc.: <https://evidence.hayesinc.com/report/dir.capsulegastroparesis1419>

Special Notes: *

This medical policy express Sentara Health Plan's determination of medical necessity of services, and they are based upon a review of currently available clinical information. These policies are used when no specific guidelines for coverage are provided by the Department of Medical Assistance Services of Virginia (DMAS). Medical Policies may be superseded by state Medicaid Plan guidelines. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

The Early and Periodic Screening, Diagnostic and Treatment (EPSDT) covers services, products, or procedures for children, if those items are determined to be medically necessary to "correct or ameliorate" (make better) a defect, physical or mental illness, or condition (health problem) identified through routine medical screening or examination, regardless of whether coverage for the same service or support is an optional or limited service under the state plan. Children enrolled in the FAMIS Program are not eligible for all EPSDT treatment services. All requests for authorization for the services described by this medical policy will be reviewed per EPSDT guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member's condition. *Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*

Keywords:

wireless capsule, shp medical 212, medical 81, endoscopy, smartpill, chromoendoscopy, swallow, device, capsule endoscopy, small intestine, digestive tract, Crohns, inflammatory bowel disease, Wireless Motility Capsule (WMC), Wireless Gastrointestinal Motility Monitoring Systems (WGMMS)